DDX53 and neoplasm: Furthermore, to evaluate the memory immune responses, the mice that received one, two, or three doses of pBARF1 and survived tumor challenge were randomized and rechallenged with either CT26 or CT26-BARF1 cells on day 446 post-initial challenge (Figures 5A and 5C).